基本信息
浏览量:7
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
2000 - 2004 Southwest University of Sci & Tech, China. [B.Sc]
2004 - 2005 State Key Laboratory of Biotherapy, China. [Research Assistant]
2005 - 2008 Laurentian University/Health Sciences North, Canada. [M.Sc]
2008 - 2013 University of Nottingham/Queens Medical Centre, UK. [Ph.D]
2012 - 2013 University of Nottingham, UK. [Post-doc]
2013 - 2017 University College London, UK. [Research Associate]
2017 - 2018 The Francis Crick Institute, UK. [Research Associate]
2018 - now The 7th Affiliated Hospital (Shenzhen), Sun Yat-Sen University, China. [PI]
After my undergrad studies in China, I went to Canada in 2005 for a M.Sc program in cancer biology offered jointly by Laurentian University and Health Sciences North (the largest hospital in north Ontario) in Sudbury with Dr. Hoyun Lee. Later in 2008, I moved to the UK for my Ph.D studies in pre-clinical oncology at the University of Nottingham/Queens Medical Centre (the largest teaching hospital nationwide) in the UK with Dr. Abdol Nateri. In 2013, I joined the esteemed Institute of Neurology at University College London as a postdoc with Prof. Sebastian Brandner who is a neuropathologist. In 2017, I joined the Francis Crick Institute (UK's flagship research institute) as a senior research associate with Dr. Axel Behrens who is a cancer stem cell expert. At the end of 2018, I moved back to China and started my own research group as an independent PI at the Seventh Affiliated Hospital of Sun Yat-sen University (SYSU, top 10 in China and known for its biomedical research and clinics) in Shenzhen, where we also launched the Tomas Lindahl Nobel Laureate Laboratory in 2019.
I have received comprehensive training in the fields of biology, pathology, and tumor modeling, with a specific focus on tumor initiation, development, and its interaction with the microenvironment. My research interests lie in understanding how metabolic or proteostatic disturbances (e.g. IDH mutation, cytokine signalling or E3 ligases) affect phenotypic plasticity through endoplasmic reticulum stress (ERS) in glioma and colorectal cancer.
Currently, my team is deeply committed to deciphering how metabolic homeostasis of neurotransmitters, lipid or cholesterol coupling to ERS determines tumour microenvironment or orchestrates neuropsychiatric diseases (NPDs), such as autism spectrum disorder (ASD). Moreover, we are actively exploring the emerging concept of the microbiome-metabolite axis as a groundbreaking hallmark that could fundamentally shape disease progression. We strongly believe that unraveling this axis could pave the way for novel therapeutic trajectories targeting both cancer and NPDs.
Our overarching goals are: 1) to identify novel diagnostic markers and therapeutic targets by mapping the intricate molecular networks of stress and response, and 2) to design and synthesize peptide drugs and first-in-class small molecule compounds, ultimately leading to the development of more effective and precise treatments for these challenging diseases. Through cutting-edge research and relentless dedication, we strive to bring transformative advancements to the field of biomedicine.
研究兴趣
论文共 88 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Oncogeneno. 17 (2024): 1-16
JOURNAL OF CELLULAR AND MOLECULAR MEDICINEno. 7 (2024): e18160-e18160
Toxicology and Applied Pharmacology (2024): 116800-116800
Jian Jiang,Dilong Wang,Youheng Jiang,Xiuyan Yang, Runfeng Sun,Jinlong Chang,Wenhui Zhu,Peijia Yao,Kun Song,Shuwen Chang,Hong Wang, Lei Zhou,
Microbiomeno. 1 (2024): 1-22
Zhang Fu,Xiuyan Yang,Youheng Jiang,Xinliang Mao, Hualin Liu, Yanming Yang, Jia Chen, Zhumei Chen,Huiliang Li,Xue-Song Zhang,Xinjun Mao,Ningning Li,
Journal of Experimental & Clinical Cancer Researchno. 1 (2024): 1-21
TOXICOLOGY AND APPLIED PHARMACOLOGY (2024)
Biomoleculesno. 3 (2023): 479-479
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn